Cargando…

Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis

BACKGROUND: Sarcomas constitute a heterogeneous group of tumors with different clinical behaviors and variable responses to systemic therapies. Recent immunotherapy studies with PD1 inhibitors (PD1i) show promising results with use in certain soft-tissue sarcomas; however, the clinical and molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quiroga, Dionisia, Liebner, David A., Philippon, Jennifer S., Hoffman, Sarah, Tan, Yubo, Chen, James L., Lenobel, Scott, Wakely, Paul E., Pollock, Raphael, Tinoco, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275332/ https://www.ncbi.nlm.nih.gov/pubmed/32503455 http://dx.doi.org/10.1186/s12885-020-07021-x

Ejemplares similares

Clinical markers of immunotherapy outcomes in advanced sarcoma
por: Husain, Marium, et al.
Publicado: (2023)

Prospective Evaluation of the Concordance of Commercial Circulating Tumor DNA Alterations with Tumor-Based Sequencing across Multiple Soft Tissue Sarcoma Subtypes
por: Demoret, Bryce, et al.
Publicado: (2019)

Emerging Trends in Immunotherapy for Adult Sarcomas
por: Husain, Marium, et al.
Publicado: (2023)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
por: You, Yang, et al.
Publicado: (2021)

Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events
por: Speece, N.J., et al.
Publicado: (2022)

Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
por: Tian, Zhichao, et al.
Publicado: (2020)

Mediastinal sarcomas: experience using fine needle aspiration cytopathology
por: Lott-Limbach, Abberly A., et al.
Publicado: (2020)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Recent advances and application of PD-1 blockade in sarcoma
por: Zuo, Wenli, et al.
Publicado: (2019)

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
por: Tian, Zhichao, et al.
Publicado: (2022)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

The Universe is in the details
por: Wakely, Scott
Publicado: (2006)

Reliable Establishment of Human Sarcoma Xenografts in the Nude Rat
por: Tinkey, Peggy T., et al.
Publicado: (1999)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Cancer-Derived Extracellular Vesicles: Their Role in Sarcoma
por: Adib, Anita, et al.
Publicado: (2022)

Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens
por: Hay, Margaret A., et al.
Publicado: (2020)

Case report: Pulmonary synovial sarcoma in a long-term survivor of childhood Hodgkin lymphoma
por: Shilo, Konstantin, et al.
Publicado: (2023)

Sarcoma osteogénico (Revisión Bibliográfica)/
por: Romero Tinoco, Pablo
Publicado: (1990)

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
por: Lang, David, et al.
Publicado: (2021)

Olomoucine II, New Effective CDK Inhibitor with Strong Cytotoxic Properties
por: Lenobel, R., et al.
Publicado: (2001)

Morbidity and Mortality after Surgery for Retroperitoneal Sarcoma
por: Ruff, Samantha M., et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
por: Sukumar, Jasmine, et al.
Publicado: (2021)

Multivisceral resection of primary multifocal retroperitoneal sarcomas: a retrospective study from a high-volume sarcoma center
por: Zhuang, Aobo, et al.
Publicado: (2023)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
por: Schmitt, Thomas, et al.
Publicado: (2010)

Patient-derived xenografts for individualized care in advanced sarcoma
por: Stebbing, Justin, et al.
Publicado: (2014)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study
por: Xu, Fei, et al.
Publicado: (2021)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study
por: Tan, Zhichao, et al.
Publicado: (2022)

PD-1 Inhibitors in the Advanced Esophageal Cancer
por: Hong, Ye, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study
por: Liu, Zengjun, et al.
Publicado: (2023)

PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
por: Wei, Qing, et al.
Publicado: (2020)

Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study
por: Cheng, Mingxia, et al.
Publicado: (2022)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
por: Lessi, Federica, et al.
Publicado: (2023)

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
por: Lang, David, et al.
Publicado: (2019)

Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience
por: Liu, Jie, et al.
Publicado: (2021)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sraj0kppt2ppfrtps7n5ag5gt0